Akin Ozturk
Research Subjects
Research Interests
Akin Ozturk has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Murat Kavas
Department of Immunology and Allergy, University of Health Sciences, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital
3 shared publications - Cansel Atinkaya
Department of Thoracic Surgery, Faculty of Medicine, Pamukkale University, Denizli, Turkey
2 shared publications - Faruk Tas
Department of Medical Oncology, Institute of Oncology, University of Istanbul, Istanbul, TURKEY
2 shared publications - Kayhan Erturk
Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Taşcioğlu City Hospital, İstanbul, Turkey
2 shared publications Abdilkerim Oyman
Department of Medical Oncology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey
1 shared publication- Abdurrahman Yılmaz
Department of Chest Diseases, Sancaktepe İlhan Varank Training and Research Hospital, Health Sciences University, Istanbul, Türkiye
1 shared publication
Latest Publications
- 1 May 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (5) , 505-511
An example of timely palliative care: survival results of pleural mesothelioma cases followed in our palliative care clinic
Aim Malignant pleural mesothelioma (MPM) is a rare and deadly cancer with a poor prognosis. This study aimed to assess the effect of timely palliative care on survival and symptom management in MPM patients. We hypothesized that early palliative intervention could alleviate symptom burden and enhance survival outcomes. Methods A retrospective analysis was conducted on 66 MPM patients referred to the Palliative Care Service between 2016 and 2023. Patients were categorized as inpatients or outpatients. Data on demographics, cancer history, disease stage, treatment, and survival were collected. Kaplan-Meier survival analysis, chi-square tests, and t-tests were used to compare outcomes. Results The average survival duration was 20.9 ± 20.4 months, with a 5-year survival rate of 25.8%, exceeding previous reports. Inpatients, despite experiencing a higher symptom burden, lived more than six months longer than outpatients. Weight loss emerged as the strongest predictor of mortality, while age, gender, and BMI had no significant effect on survival. Conclusion Timely palliative care significantly improves survival outcomes in MPM patients by effectively managing symptoms and providing holistic care. Further randomized controlled trials are needed to confirm these findings and optimize strategies, especially in nutrition and symptom management. Early integration of palliative care is essential for better clinical outcomes in mesothelioma patients.
- 1 May 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (5) , 505-511
An example of timely palliative care: survival results of pleural mesothelioma cases followed in our palliative care clinic
Aim Malignant pleural mesothelioma (MPM) is a rare and deadly cancer with a poor prognosis. This study aimed to assess the effect of timely palliative care on survival and symptom management in MPM patients. We hypothesized that early palliative intervention could alleviate symptom burden and enhance survival outcomes. Methods A retrospective analysis was conducted on 66 MPM patients referred to the Palliative Care Service between 2016 and 2023. Patients were categorized as inpatients or outpatients. Data on demographics, cancer history, disease stage, treatment, and survival were collected. Kaplan-Meier survival analysis, chi-square tests, and t-tests were used to compare outcomes. Results The average survival duration was 20.9 ± 20.4 months, with a 5-year survival rate of 25.8%, exceeding previous reports. Inpatients, despite experiencing a higher symptom burden, lived more than six months longer than outpatients. Weight loss emerged as the strongest predictor of mortality, while age, gender, and BMI had no significant effect on survival. Conclusion Timely palliative care significantly improves survival outcomes in MPM patients by effectively managing symptoms and providing holistic care. Further randomized controlled trials are needed to confirm these findings and optimize strategies, especially in nutrition and symptom management. Early integration of palliative care is essential for better clinical outcomes in mesothelioma patients.
- 17 February 2024
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (2) , 208-217
Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer
Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy. A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively. BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, p = 0.0001); however, BMI (HR: 1.035, p = 0.8), WL (HR: 0.857, p = 0.5), and ALB (HR: 0.743, p = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, p = 0.0001), WL (HR: 1.677, p = 0.001), and ALB (HR: 0.680, p = 0.007) had an impact on survival, but BMI did not (HR: 0.791, p = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, p = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, p = 0.0001), WL (HR: 1.667, p = 0.001), and a low ALB level (HR: 0.680, p = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, p = 0.001). Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.
- 17 February 2024
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (2) , 208-217
Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer
Body mass index (BMI) and serum albumin (ALB) level are long-established markers that reflect the nutritional status and eventually the prognosis of cancer patients. The objective of the study was to determine the clinical significance of these factors and specify their roles in outcomes compared with performance status (PS) and weight loss (WL), which are considered the most significant patient-related prognostic factors in small cell lung cancer (SCLC) treated with platinum-etoposide-based chemotherapy. A total of 378 patients with SCLC were enrolled in the study and analyzed retrospectively. BMI values were similar by clinical stage, whereas the percentages of the patients with WL, low serum ALB, and particularly poor (≥2) PS were significantly higher in patients with extended disease SCLC (ED-SCLC) compared to those with limited disease SCLC (LD-SCLC). In LD-SCLC, patients with poor PS lived for a significantly shorter time than patients with good PS (HR: 7.791, p = 0.0001); however, BMI (HR: 1.035, p = 0.8), WL (HR: 0.857, p = 0.5), and ALB (HR: 0.743, p = 0.3) had no significant effect on the outcome. In ED-SCLC, PS (HR: 4.257, p = 0.0001), WL (HR: 1.677, p = 0.001), and ALB (HR: 0.680, p = 0.007) had an impact on survival, but BMI did not (HR: 0.791, p = 0.08). In LD-SCLC, the univariate analysis showed that only poor PS was correlated with increased mortality (HR: 7.791, p = 0.0001); yet it lost significance in multivariate analysis. In ED-SCLC, poor PS (HR: 4.257, p = 0.0001), WL (HR: 1.667, p = 0.001), and a low ALB level (HR: 0.680, p = 0.007) were shown to be factors for poor prognosis in the univariate analysis; yet only PS remained significant in multivariate analysis (HR: 2.286, p = 0.001). Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.
- 22 January 2024
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (7) , 607-612
Timing of chemotherapy after diagnosis of small cell lung cancer
Systemic chemotherapy is the backbone of therapeutic management in small cell lung cancer (SCLC) and delay of treatment may lead to adverse patient outcomes. This study was conducted to determine the time elapsed between pathological diagnosis and initiation of chemotherapy in SCLC patients and to evaluate its clinical significance. A total of 323 pathologically confirmed SCLC patients were enrolled in the study and analyzed retrospectively. The median value of the patients' time to treatment was used as the cut-off value in distinguishing between early and late chemotherapy. The median (range) of the time interval between the pathological diagnosis and the initiation of chemotherapy was 18 days (1-257). Compared with other clinical variables, only the performance status of patients was significantly associated with the time from diagnosis to initiation of chemotherapy; patients with poor prognostic factors received chemotherapy earlier than other patients (32.9 vs 18.9%, p = 0.004, and 14.5 vs 19 days, p = 0.006). Although patients who received early treatment were found to live less, there was no statistically significant difference in overall survival in patients according to the timing of chemotherapy administration (p = 0.08). In conclusion, there are controversial results about the timing of chemotherapy administration to SCLC patients. More standardized definitions and guides for calculation of the time interval between diagnosis and treatment are needed to better understand the delays in the treatment of patients with clinically rapidly disseminating SCLC.
- 22 January 2024
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (7) , 607-612
Timing of chemotherapy after diagnosis of small cell lung cancer
Systemic chemotherapy is the backbone of therapeutic management in small cell lung cancer (SCLC) and delay of treatment may lead to adverse patient outcomes. This study was conducted to determine the time elapsed between pathological diagnosis and initiation of chemotherapy in SCLC patients and to evaluate its clinical significance. A total of 323 pathologically confirmed SCLC patients were enrolled in the study and analyzed retrospectively. The median value of the patients' time to treatment was used as the cut-off value in distinguishing between early and late chemotherapy. The median (range) of the time interval between the pathological diagnosis and the initiation of chemotherapy was 18 days (1-257). Compared with other clinical variables, only the performance status of patients was significantly associated with the time from diagnosis to initiation of chemotherapy; patients with poor prognostic factors received chemotherapy earlier than other patients (32.9 vs 18.9%, p = 0.004, and 14.5 vs 19 days, p = 0.006). Although patients who received early treatment were found to live less, there was no statistically significant difference in overall survival in patients according to the timing of chemotherapy administration (p = 0.08). In conclusion, there are controversial results about the timing of chemotherapy administration to SCLC patients. More standardized definitions and guides for calculation of the time interval between diagnosis and treatment are needed to better understand the delays in the treatment of patients with clinically rapidly disseminating SCLC.
- Open Access
- 5 March 2023
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 8 (1) , 122-126
Erken Evre Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Tiyol-Disülfid Homeostazisin Prognoz Üzerine Etkisi
Objective: Lung cancer has a poor prognosis. Thiol groups with high antioxidant capacity are converted to disulfide bonds through biochemical reactions that neutralize different oxidant compounds. The thiol-disulfide (SH-SS) homeostasis has significant effects on cell mechanisms, transcription, and apoptosis. Here we present the prognostic role of dynamic SH-SS homeostasis in patients operated for NSCLC. Materials and Methods: Patients operating for early-stage NSCLC were prospectively analyzed. SH-SS homeostasis tests were measured using the automated spectrophotometric method. Results: This study enrolled 138 subjects, including 77 patients and 61 healthy controls. Native thiol and total thiol levels were significantly lower in the patient group. The disulfide-to-native thiol ratio, which is an indicator of oxidative stress in SH-SS homeostasis, also reached a level of statistical significance in the patient group (p<0.001). According to the cut-off values (305 and 326.3), the median overall survival rate was significantly shorter in patients with low native thiol and total thiol levels (p<0.001). Conclusions: This study demonstrated decreased native thiol and total thiol levels as well as decreased disulfide levels and SS/SH ratio in early-stage NSCLC. Impaired SH-SS homeostasis may contribute to lung cancer pathogenesis and poor prognosis because of enhanced oxidative stress.
- 5 March 2023
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 8 (1) , 122-126
Open AccessErken Evre Küçük Hücreli Dışı Akciğer Kanserli Hastalarda Tiyol-Disülfid Homeostazisin Prognoz Üzerine Etkisi
Objective: Lung cancer has a poor prognosis. Thiol groups with high antioxidant capacity are converted to disulfide bonds through biochemical reactions that neutralize different oxidant compounds. The thiol-disulfide (SH-SS) homeostasis has significant effects on cell mechanisms, transcription, and apoptosis. Here we present the prognostic role of dynamic SH-SS homeostasis in patients operated for NSCLC. Materials and Methods: Patients operating for early-stage NSCLC were prospectively analyzed. SH-SS homeostasis tests were measured using the automated spectrophotometric method. Results: This study enrolled 138 subjects, including 77 patients and 61 healthy controls. Native thiol and total thiol levels were significantly lower in the patient group. The disulfide-to-native thiol ratio, which is an indicator of oxidative stress in SH-SS homeostasis, also reached a level of statistical significance in the patient group (p<0.001). According to the cut-off values (305 and 326.3), the median overall survival rate was significantly shorter in patients with low native thiol and total thiol levels (p<0.001). Conclusions: This study demonstrated decreased native thiol and total thiol levels as well as decreased disulfide levels and SS/SH ratio in early-stage NSCLC. Impaired SH-SS homeostasis may contribute to lung cancer pathogenesis and poor prognosis because of enhanced oxidative stress.
- Open Access
- 14 May 2022
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 22 (6) , 982-991
The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
- 14 May 2022
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 22 (6) , 982-991
Open AccessThe effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
Erlotinib, a tyrosine kinase inhibitor, has been shown to improve the survival of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. Sarcopenia is a status with increasing importance in lung cancer, and it may predict a poor prognosis. We aimed to evaluate the impact of sarcopenia on erlotinib therapy and prognosis in patients with EGFR-mutated (exon 19 or 21 L858R) metastatic lung adenocarcinoma. Sarcopenia was defined as skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men. The patient characteristics, inflammation parameters, clinical and survival outcomes of the erlotinib therapy were examined according to sarcopenia status. We also analyzed the erlotinib treatment-related toxicity. Seventy-two patients were included in our retrospective study, and the mean age of the patients was 63.7 years. A total of 39 (54.2%) patients were diagnosed with sarcopenia. Patients with sarcopenia had a poor prognosis and had a shorter median progression-free survival (PFS) than patients without sarcopenia (10.5 months vs. 21.8 months, p=0.002). Sarcopenia (HR 2.08) and C-reactive protein > 6.5 mg/L (HR 2.57) were determined as independent poor prognostic factors for PFS of erlotinib therapy. Treatment-related toxicity occurred in 34.7% of patients treated with erlotinib, and sarcopenia did not significantly affect treatment-related toxicity. We also found that sarcopenia significantly affected the response to erlotinib. The expected survival outcomes may be low when erlotinib therapy is used in patients with sarcopenia and metastatic lung adenocarcinoma. This study showed that survival and clinical outcomes could be better predicted by detecting sarcopenia in patients with lung cancer using erlotinib.
- 4 January 2020
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 63 (3) , 238-243
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 – September 2018, EGFR, ALK, and ROS1 alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1,904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK and ROS1 rearrangements were 14.5%, 3.7% and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48,7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.
- 4 January 2020
- Published by Wolters Kluwer Health in Journal of Occupational and Environmental Medicine
- Vol. 63 (3) , 238-243
Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma
Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 – September 2018, EGFR, ALK, and ROS1 alterations, demographic characteristics, asbestos exposure, and asbestos-related radiological findings of 1,904 patients with lung adenocarcinoma were recorded. Results: The frequencies of EGFR mutations, ALK and ROS1 rearrangements were 14.5%, 3.7% and 0.9%, respectively. The rates of EGFR mutations and ALK rearrangements were more frequent in asbestos exposed non-smokers (48,7% and 9%, respectively). EGFR mutation rate was correlated to female gender and not-smoking, ALK rearrangement rate was correlated to younger age, not-smoking and a history of asbestos exposure. Conclusions: The higher rate of ALK rearrangements in asbestos-exposed lung adenocarcinoma cases shows that asbestos exposure may most likely cause genetic alterations that drive pulmonary adenocarcinogenesis.
- 20 June 2019
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 20 (3) , 203-205
Rare Lung Tumors: Alveolar Adenoma-Four Case Reports
Turkthoracj, Turkish Thoracic Journal
- 20 June 2019
- Published by Galenos Yayinevi in Turkish Thoracic Journal
- Vol. 20 (3) , 203-205
Rare Lung Tumors: Alveolar Adenoma-Four Case Reports
Turkthoracj, Turkish Thoracic Journal